In a major boost for the Indian healthcare sector, the Chennai-based diagnostic company, Neuberg Diagnostics has raised INR 940 crore investment from Kotak Strategic Situations India Fund II, managed by Kotak Alternate Asset Managers. This marks the largest primary fundraising ever seen in India’s diagnostics industry, coming at a critical time as Neuberg preps for its IPO next year.
This deal represents Neuberg’s first venture into private equity funding, a significant leap forward under the leadership of Dr. GSK Velu. The investment not only showcases confidence in Neuberg’s vision but also aims to propel the company to become India’s leading diagnostics chain.
Strategic Acquisitions to Fuel Expansion
Neuberg’s narrative has been one of bold ambition and technological innovation. Dr. Velu, without mincing words, outlined how this new capital injection would be used. The focus is on personalized medicine, integrated diagnostics, and growth through mergers and acquisitions.
“This investment will significantly boost our capabilities, allowing us to expand our footprint across India, making high-quality diagnostics accessible to all,” Dr. Velu stated.
With an existing network of over 250 labs spread across 250 cities, processing upwards of 20 million tests each year, Neuberg has established itself as one of the top four diagnostic services providers in India, with a strong presence in genomics.
Kotak’s Confidence in Neuberg’s Vision
Kotak’s backing adds substantial credibility to Neuberg’s expansion plans. The deal, brokered by O3 Capital, reflects a trend of strategic investments in healthcare, particularly in diagnostics, which is becoming increasingly pivotal in modern medical practice.
Neuberg Diagnostic – Overview
Since its inception in 2017, Neuberg Diagnostics has grown at a breakneck pace, establishing itself as a pioneer in integrated diagnostics. Offering more than 5,000 types of pathology tests and health check-up packages ranging from INR 1,000 to INR 8,500, Neuberg isn’t just about volume but quality and specialization.
Centres of excellence in genomics, proteomics, metabolomics, and other specialized areas have cemented Neuberg’s reputation. From newborn screenings to reproductive genomics, the company’s expertise spans transplantation immunology, haemato-oncology, and histopathology.
Strategic collaborations have been central to Neuberg’s strategy. In 2024, the company merged with Supratech Reference Laboratory in Ahmedabad and Anand Reference Laboratory in Bengaluru, while a partnership with Kolkata-based Pulse Diagnostics extended its reach into eastern India.
Neuberg’s IPO on the Horizon
Kotak Securities’ investment in Neuberg Diagnostics is a launchpad for the company’s grander ambitions. As the IPO looms, the company is intensifying efforts to scale up both domestically and abroad, keeping personalized and integrated diagnostics at the core of its strategy.
Neuberg’s path has been marked by strategic risks and ambitious plays. Now, with the robust support from Kotak, Neuberg Diagnostics is poised not just to meet the upcoming challenges but to redefine the landscape of healthcare diagnostics, not only in India but potentially worldwide.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.
